Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
BIO-THERA SOLUTIONS, LTD. currently faces 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 7 distinct examiners, meaning every pending action is being handled by a different individual. This high level of examiner diversity across 4 distinct art units suggests a broad and varied set of technologies or applications within the pharmaceutical space.
The busiest examiner, CANELLA, KAREN A, is responsible for 1 pending office action. In a portfolio where the total pending office actions number 7, the fact that the busiest examiner only has 1 action highlights the fragmentation of the prosecution workload. No single examiner holds more than 1 action, as each of the 7 distinct examiners manages exactly 1 action.
For the applicant, navigating 4 distinct art units requires a versatile approach to prosecution, as each unit may have different standards. The presence of 7 pending office actions indicates a significant level of engagement with the patent office. Because each action is with a different examiner, the company cannot rely on a single relationship to streamline its 7 pending cases.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (14%) |
| Double-patenting + other | 4 (57%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| LU, CHENG | 1 | 54.1% | +64.1% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
| SKELDING, ZACHARY S | 1 | 59.7% | +41.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701217 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | CANELLA, KAREN A | — |
| 18275747 | ANTI-IL-5 ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF | BENAVIDES, JENNIFER ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701217 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | CANELLA, KAREN A | — |
| 18697291 | ANTI-B7-H3 ANTIBODY AND APPLICATION THEREOF | LU, CHENG | — |
| 18681485 | USE OF ANTI-PD-L1/CD47 BISPECIFIC ANTIBODY IN TREATMENT OF DISEASES | CUNNINGCHEN, KATHLEEN MARY | — |
| 18275747 | ANTI-IL-5 ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF | BENAVIDES, JENNIFER ANN | — |
| 18035591 | BISPECIFIC ANTIBODY AND USE THEREOF | STOICA, ELLY GERALD | — |
| 18019918 | ANTI-PD-L1 ANTIBODY AND USE THEREOF | STONEBRAKER, ALYSSA RAE | — |
| 18045946 | LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASES | SKELDING, ZACHARY S | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1647 | 1 |
| 1642 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701217 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | CANELLA, KAREN A | — | §102§112Other | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18697291 | ANTI-B7-H3 ANTIBODY AND APPLICATION THEREOF | LU, CHENG | — | §112DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18681485 | USE OF ANTI-PD-L1/CD47 BISPECIFIC ANTIBODY IN TREATMENT OF DISEASES | CUNNINGCHEN, KATHLEEN MARY | — | §102§103§112DP | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18275747 | ANTI-IL-5 ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §103§112 | Final Rejection | — | Pending | Aug 03, 2023 |
| 18035591 | BISPECIFIC ANTIBODY AND USE THEREOF | STOICA, ELLY GERALD | 1647 | §112DP | Final Rejection | — | Pending | May 05, 2023 |
| 18019918 | ANTI-PD-L1 ANTIBODY AND USE THEREOF | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Feb 06, 2023 |
| 18045946 | LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASES | SKELDING, ZACHARY S | 1644 | §112 | Non-Final OA | — | Pending | Oct 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial